AcadeMab announced the initiation of Phase 1 clinical trial of an anti-EpCAM monoclonal antibody, AM-928 for treatment of patients with advanced solid tumors

The first subject of this trail has enrolled, and a total of 30 subjects are expected to participate in this clinical trial

AcadeMab Biomedical and Academia Sinica enter into exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids

AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term.

研生生醫3年抗體新藥進IND 再引mRNA疫苗技術雙引擎發展

研⽣精準醫療抗體新藥AM-928 於年初取得美國IND後，並進一步自中研院引進mRNA疫苗平台成為研生的另一顆引擎。

研生精準醫療抗體新藥AM-928取得美國IND 對多種癌症治療具臨床潛力

研⽣精準醫療抗體新藥AM-928 取得美國IND
對多種癌症治療具臨床潛⼒ 將展開一期臨床試驗

AcadeMab focusing on COVID-19 antibody drug

後疫情時代抗體藥物開發策略(直接影片)

Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy

AcadeMab makes its mark at 2022 BIO USA

Visitors to the 2022 BIO International Convention in San Diego check out at booth of AcadeMab Biomedical Inc. at the Taiwan Pavilionto market the products and seek new business opportunities.